Lonza Group AG

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CH0013841017
CHF
523.20
-1 (-0.19%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Lonza Group AG stock-summary
stock-summary
Lonza Group AG
Pharmaceuticals & Biotechnology
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
Company Coordinates stock-summary
Company Details
Muenchensteinerstrasse 38 , BASEL None : 4002
stock-summary
Tel: 41 61 316811141 61 3168540
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 9 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Albert Baehny
Chairman of the Board, Member of the Executive Board
Mr. Christoph Maeder
Lead Independent Member of the Board
Prof. Dr.-Ing. Werner Bauer
Independent Member of the Board
Ms. Angelica Kohlmann
Independent Member of the Board
Ms. Barbara Richmond
Independent Member of the Board
Mr. Juergen Steinemann
Independent Member of the Board
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CHF 38,907 Million ()

stock-summary
P/E

48.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.77%

stock-summary
Debt Equity

0.43

stock-summary
Return on Equity

9.46%

stock-summary
Price to Book

4.51